Published in Br J Pharmacol on March 18, 2015
Use of a Non-medicated Plaster in Chronic Lumbar Back Pain. (CERFIT) | NCT04651426
The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands. Nucleic Acids Res (2013) 9.61
Metabolism and disposition kinetics of nicotine. Pharmacol Rev (2005) 6.66
Current status and future potential of transdermal drug delivery. Nat Rev Drug Discov (2004) 3.41
Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol (2007) 2.99
Permeability of the skin. Physiol Rev (1971) 2.58
The Concise Guide to PHARMACOLOGY 2013/14: overview. Br J Pharmacol (2013) 2.48
A 100,000-year-old ochre-processing workshop at Blombos Cave, South Africa. Science (2011) 2.43
Opioid overdose in a patient using a fentanyl patch during treatment with a warming blanket. Anesth Analg (2001) 2.39
A sumatriptan iontophoretic transdermal system for the acute treatment of migraine. Headache (2012) 2.15
Interindividual variability in the metabolism and cardiovascular effects of nicotine in man. J Pharmacol Exp Ther (1982) 2.12
Estimating skin permeability from physicochemical characteristics of drugs: a comparison between conventional models and an in vivo-based approach. Int J Pharm (2009) 2.09
Transdermal drug delivery: overcoming the skin's barrier function. Pharm Sci Technolo Today (2000) 2.08
The origins and evolution of "controlled" drug delivery systems. J Control Release (2008) 2.05
Nitric oxide in immunity and inflammation. Int Immunopharmacol (2001) 1.91
The pharmacokinetics of oxybutynin in man. Eur J Clin Pharmacol (1988) 1.83
Microneedles permit transdermal delivery of a skin-impermeant medication to humans. Proc Natl Acad Sci U S A (2008) 1.77
Regional variation in percutaneous penetration of 14C cortisol in man. J Invest Dermatol (1967) 1.75
Skin adhesives and skin adhesion. 1. Transdermal drug delivery systems. Biomaterials (1998) 1.53
Transdermal scopolamine in the prevention of motion sickness at sea. Clin Pharmacol Ther (1981) 1.53
Transdermal fentanyl: pharmacology and toxicology. J Med Toxicol (2009) 1.41
Application of the Millon reaction to the determination of chlorophenols in body fluids and tissues. Biochem J (1943) 1.40
Transdermal drug pharmacokinetics in man: Interindividual variability and partial prediction. Int J Pharm (2008) 1.39
Pharmacokinetics and pharmacodynamics of transdermal dosage forms of 17 beta-estradiol: comparison with conventional oral estrogens used for hormone replacement. Am J Obstet Gynecol (1985) 1.37
ACR guidance document on MR safe practices: 2013. J Magn Reson Imaging (2013) 1.35
Passive skin penetration enhancement and its quantification in vitro. Eur J Pharm Biopharm (2001) 1.34
Sustained effects of nitroglycerin ointment in patients with angina pectoris. Circulation (1974) 1.34
Potent immunity to low doses of influenza vaccine by probabilistic guided micro-targeted skin delivery in a mouse model. PLoS One (2010) 1.27
Parathyroid hormone (1-34)-coated microneedle patch system: clinical pharmacokinetics and pharmacodynamics for treatment of osteoporosis. Pharm Res (2010) 1.21
Human pharmacokinetics of intravenous, sublingual, and buccal buprenorphine. J Anal Toxicol (1996) 1.16
TESTOSTERONE PRODUCTION AND METABOLIC CLEARANCE RATES WITH VOLUMES OF DISTRIBUTION IN NORMAL ADULT MEN AND WOMEN. Acta Endocrinol (Copenh) (1965) 1.14
Postoperative analgesia with fentanyl: pharmacokinetics and pharmacodynamics of constant-rate i.v. and transdermal delivery. Br J Anaesth (1988) 1.12
Fatal outcome in a child after ingestion of a transdermal fentanyl patch. Int J Legal Med (2006) 1.11
THE ANTIPERSPIRANT ACTION OF TOPICALLY APPLIED ANTICHOLINERGICS. J Invest Dermatol (1964) 1.10
Skin penetration enhancers. Int J Pharm (2013) 1.09
Molecular size as the main determinant of solute maximum flux across the skin. J Invest Dermatol (2004) 1.08
Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice-daily capsules in Alzheimer's disease patients. Clin Pharmacol Ther (2007) 1.08
Clinical pharmacokinetics of drugs used to treat urge incontinence. Clin Pharmacokinet (2003) 1.07
Nicotine absorption by workers harvesting green tobacco. Lancet (1975) 1.07
Pressure-sensitive adhesives for transdermal drug delivery systems. Pharm Sci Technolo Today (1999) 1.07
Fentanyl transdermal system overdose secondary to cutaneous hyperthermia. Anesth Analg (1993) 1.06
Estrogen replacement therapy by transdermal estradiol administration. Am J Obstet Gynecol (1983) 1.05
Pharmacokinetics of single and multiple doses of ethinyl estradiol and levonorgestrel in relation to smoking. Clin Pharmacol Ther (1988) 1.04
Transdermal nicotine reduces cigarette craving and nicotine preference. Clin Pharmacol Ther (1985) 1.03
Outbreak of accidental hexachlorophene poisoning in France. Lancet (1982) 1.03
Development of skin barrier function in premature infants. J Invest Dermatol (1998) 1.02
Adhesive properties: a critical issue in transdermal patch development. Expert Opin Drug Deliv (2011) 1.02
The Prevention and Treatment of Motion Sickness I. Seasickness. Science (1949) 1.02
Pharmacokinetics of a rivastigmine transdermal patch formulation in healthy volunteers: relative effects of body site application. J Clin Pharmacol (2007) 1.02
Small doses, big problems: a selected review of highly toxic common medications. Pediatr Emerg Care (1993) 1.01
Clinical pharmacokinetics of clonidine. Clin Pharmacokinet (1988) 1.01
Fatal fentanyl intoxication following excessive transdermal application. J Forensic Sci (1997) 1.01
A pharmacokinetic crossover study to compare the absorption characteristics of three transdermal nicotine patches. Pharmacol Biochem Behav (2000) 1.00
Pharmacokinetics of a contraceptive patch (Evra/Ortho Evra) containing norelgestromin and ethinyloestradiol at four application sites. Br J Clin Pharmacol (2002) 1.00
Cutaneous pharmacokinetics: 10 steps to percutaneous absorption. Drug Metab Rev (1983) 0.99
Transdermal delivery of narcotic analgesics: pH, anatomical, and subject influences on cutaneous permeability of fentanyl and sufentanil. Pharm Res (1990) 0.98
Transdermal fentanyl abuse and misuse. Am J Emerg Med (2002) 0.98
Percutaneous drug absorption in the newborn: hazards and uses. Clin Perinatol (1987) 0.96
Transdermal delivery of narcotic analgesics: comparative permeabilities of narcotic analgesics through human cadaver skin. Pharm Res (1989) 0.96
Pharmacokinetics. Pharmacokinetic factors affecting epidermal penetration and percutaneous adsorption. Clin Pharmacol Ther (1974) 0.96
Testosterone treatment comes of age: new options for hypogonadal men. Clin Endocrinol (Oxf) (2006) 0.96
The bioavailability of oral nitroglycerin. J Pharm Sci (1986) 0.96
The treatment of angina pectoris with a nitroglycerin ointment. Am J Med Sci (1955) 0.95
Polymethacrylates as crystallization inhibitors in monolayer transdermal patches containing ibuprofen. Eur J Pharm Biopharm (2005) 0.92
Practical considerations for optimal transdermal drug delivery. Am J Health Syst Pharm (2012) 0.92
Exposure to high ambient temperature increases absorption and plasma concentrations of transdermal nicotine. Clin Pharmacol Ther (1996) 0.92
Topical bioavailability of methyl salicylate. Aust N Z J Med (1982) 0.91
Permeability of human epidermis to phenolic compounds. J Pharm Pharmacol (1977) 0.91
Bioavailability of orally administered sex steroids used in oral contraception and hormone replacement therapy. Contraception (1996) 0.90
Transdermal fentanyl for postoperative pain management. A double-blind placebo study. JAMA (1989) 0.89
Transdermal administration of nicotine. Drug Alcohol Depend (1984) 0.89
Green-tobacco sickness. An illness of tobacco harvesters. JAMA (1974) 0.89
Pharmacokinetics of transdermally delivered clonidine. Clin Pharmacol Ther (1985) 0.89
Transdermal nitroglycerin patches in angina pectoris. Dose titration, duration of effect, and rapid tolerance. Ann Intern Med (1986) 0.88
The refinement of uncertainty/safety factors in risk assessment by the incorporation of data on toxicokinetic variability in humans. Toxicol Sci (2005) 0.88
Functional skin adaptation in infancy - almost complete but not fully competent. Exp Dermatol (2010) 0.88
Topical penetration of commercial salicylate esters and salts using human isolated skin and clinical microdialysis studies. Br J Clin Pharmacol (1998) 0.88
Initial evaluation of transdermal timolol: serum concentrations and beta-blockade. J Cardiovasc Pharmacol (1985) 0.88
Analgesic efficacy of sustained release paracetamol in patients with osteoarthritis of the knee. Br J Clin Pharmacol (2002) 0.88
Transdermal delivery of fentanyl from matrix and reservoir systems: effect of heat and compromised skin. J Pharm Sci (2010) 0.87
Enhanced transdermal delivery of testosterone across nonscrotal skin produces physiological concentrations of testosterone and its metabolites in hypogonadal men. J Clin Endocrinol Metab (1992) 0.87
The role of microneedles for drug and vaccine delivery. Expert Opin Drug Deliv (2014) 0.87
Modelling dermal drug distribution after topical application in human. Pharm Res (2011) 0.86
Percutaneous absorption of topically applied NSAIDS and other compounds: role of solute properties, skin physiology and delivery systems. Inflammopharmacology (1999) 0.86
Transdermal drug delivery systems and skin sensitivity reactions. Incidence and management. Am J Clin Dermatol (2001) 0.86
Transdermal scopolamine for prevention of motion sickness : clinical pharmacokinetics and therapeutic applications. Clin Pharmacokinet (2006) 0.85
Prevention of experimental motion sickness by scopolamine absorbed through the skin. Aviat Space Environ Med (1976) 0.85
Transdermal drug delivery: 30+ years of war and still fighting! J Control Release (2014) 0.85
Fentanyl use among street drug users in Toronto, Canada: behavioural dynamics and public health implications. Int J Drug Policy (2008) 0.84
Plasma levels of nitroglycerin generated by three nitroglycerin patch preparations, Nitradisc, Transiderm-Nitro and Nitro-Dur and one ointment formulation, Nitrobid. Br J Clin Pharmacol (1986) 0.84
Clinical pharmacokinetics of glyceryl trinitrate following the use of systemic and topical preparations. Clin Pharmacokinet (1987) 0.84
Biopharmaceutics of a new transdermal fentanyl device. Anesthesiology (1995) 0.84
Virilization of young children after topical androgen use by their parents. Pediatrics (2004) 0.84
Transdermal clonidine: therapeutic considerations. J Clin Hypertens (Greenwich) (2005) 0.83
Correlations between motor persistence and plasma levels in methylphenidate-treated boys with ADHD. Int J Neuropsychopharmacol (2001) 0.83
Pharmacokinetics and pharmacodynamics of transdermally administered clonidine. Eur J Clin Pharmacol (1984) 0.83
Androgenisation of female partners of men on medroxyprogesterone acetate/percutaneous testosterone contraception. Lancet (1984) 0.83
Twelve-month tolerability and efficacy study of NP101, the sumatriptan iontophoretic transdermal system. Headache (2012) 0.83
Antianginal effects of intravenous nitroglycerin over 24 hours. Circulation (1988) 0.83
Optimizing transdermal drug therapy. Am J Health Syst Pharm (2008) 0.83
A multicenter randomized trial of atorvastatin therapy in intensive care patients with severe sepsis. Am J Respir Crit Care Med (2013) 3.44
Continuation of statin therapy in patients with presumed infection: a randomized controlled trial. Am J Respir Crit Care Med (2010) 2.21
Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy: a multicentre pharmacokinetic study. Crit Care Med (2012) 2.04
Grey goo on the skin? Nanotechnology, cosmetic and sunscreen safety. Crit Rev Toxicol (2007) 1.95
Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia. Blood (2013) 1.87
Interventions that can reduce inappropriate prescribing in the elderly: a systematic review. Drugs Aging (2009) 1.76
Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. J Antimicrob Chemother (2009) 1.73
Dry-coated microprojection array patches for targeted delivery of immunotherapeutics to the skin. J Control Release (2009) 1.71
Intercontinental dispersal of bacteria and archaea by transpacific winds. Appl Environ Microbiol (2012) 1.65
First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis. Int J Antimicrob Agents (2009) 1.52
Free tropospheric transport of microorganisms from Asia to North America. Microb Ecol (2012) 1.46
Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept. Int J Antimicrob Agents (2010) 1.43
Quantifying pain relief following administration of a novel formulation of paracetamol (acetaminophen). J Clin Pharmacol (2010) 1.38
Nanoparticles and microparticles for skin drug delivery. Adv Drug Deliv Rev (2011) 1.36
A preliminary study of atorvastatin plasma concentrations in critically ill patients with sepsis. Intensive Care Med (2008) 1.33
Medication reviews in the community: results of a randomized, controlled effectiveness trial. Br J Clin Pharmacol (2004) 1.31
Human skin penetration of sunscreen nanoparticles: in-vitro assessment of a novel micronized zinc oxide formulation. Skin Pharmacol Physiol (2007) 1.31
Antioxidative function of L-FABP in L-FABP stably transfected Chang liver cells. Hepatology (2005) 1.29
Potent immunity to low doses of influenza vaccine by probabilistic guided micro-targeted skin delivery in a mouse model. PLoS One (2010) 1.27
Patient barriers to and enablers of deprescribing: a systematic review. Drugs Aging (2013) 1.27
Influence of elevated CO(2) on the fungal community in a coastal scrub oak forest soil investigated with terminal-restriction fragment length polymorphism analysis. Appl Environ Microbiol (2002) 1.26
In vivo methods for the assessment of topical drug bioavailability. Pharm Res (2007) 1.26
The influence of the Pharmaceutical Benefits Scheme (PBS) on inappropriate prescribing in Australian nursing homes. Pharm World Sci (2007) 1.24
Piperacillin penetration into tissue of critically ill patients with sepsis--bolus versus continuous administration? Crit Care Med (2009) 1.16
Nanopatch-targeted skin vaccination against West Nile Virus and Chikungunya virus in mice. Small (2010) 1.16
Imaging of zinc oxide nanoparticle penetration in human skin in vitro and in vivo. J Biomed Opt (2009) 1.13
People's attitudes, beliefs, and experiences regarding polypharmacy and willingness to Deprescribe. J Am Geriatr Soc (2013) 1.13
Physiologically based synthetic models of hepatic disposition. J Pharmacokinet Pharmacodyn (2006) 1.13
Cardiac troponin may be released by ischemia alone, without necrosis. Clin Chim Acta (2009) 1.11
Plasma and tissue pharmacokinetics of cefazolin in patients undergoing elective and semielective abdominal aortic aneurysm open repair surgery. Antimicrob Agents Chemother (2011) 1.09
Molecular size as the main determinant of solute maximum flux across the skin. J Invest Dermatol (2004) 1.08
Emerging strategies for the transdermal delivery of peptide and protein drugs. Expert Opin Drug Deliv (2005) 1.08
Review of deprescribing processes and development of an evidence-based, patient-centred deprescribing process. Br J Clin Pharmacol (2014) 1.03
Medication management at home: medication-related risk factors associated with poor health outcomes. Age Ageing (2005) 1.02
Enhancement of topical delivery from biodegradable nanoparticles. Pharm Res (2004) 1.01
Using pharmacokinetics and pharmacodynamics to optimise dosing of antifungal agents in critically ill patients: a systematic review. Int J Antimicrob Agents (2011) 1.00
Does Beta-lactam Pharmacokinetic Variability in Critically Ill Patients Justify Therapeutic Drug Monitoring? A Systematic Review. Ann Intensive Care (2012) 0.99
Acute human self-poisoning with imidacloprid compound: a neonicotinoid insecticide. PLoS One (2009) 0.99
Molecular mechanism of recombinant liver fatty acid binding protein's antioxidant activity. J Lipid Res (2009) 0.99
Tracing multiscale mechanisms of drug disposition in normal and diseased livers. J Pharmacol Exp Ther (2010) 0.98
Compound Astragalus and Salvia miltiorrhiza extract inhibits cell invasion by modulating transforming growth factor-beta/Smad in HepG2 cell. J Gastroenterol Hepatol (2009) 0.98
An international, multicentre survey of β-lactam antibiotic therapeutic drug monitoring practice in intensive care units. J Antimicrob Chemother (2014) 0.98
Antibiotic dosing in the 'at risk' critically ill patient: Linking pathophysiology with pharmacokinetics/pharmacodynamics in sepsis and trauma patients. BMC Anesthesiol (2011) 0.97
Ibuprofen transport into and through skin from topical formulations: in vitro-in vivo comparison. J Invest Dermatol (2006) 0.97
Modeling and simulation of hepatic drug disposition using a physiologically based, multi-agent in silico liver. Pharm Res (2007) 0.97
Changes in the concentrations of creatinine, cystatin C and NGAL in patients with acute paraquat self-poisoning. Toxicol Lett (2011) 0.96
Designing inorganic light-protective skin nanotechnology products. J Biomed Nanotechnol (2010) 0.95
Herb-drug interactions: in vivo and in vitro effect of Shenmai injection, a herbal preparation, on the metabolic activities of hepatic cytochrome P450 3A1/2, 2C6, 1A2, and 2E1 in rats. Planta Med (2009) 0.95
Analysis of the metabolic deterioration of ex vivo skin from ischemic necrosis through the imaging of intracellular NAD(P)H by multiphoton tomography and fluorescence lifetime imaging microscopy. J Biomed Opt (2010) 0.94
Cationic drug pharmacokinetics in diseased livers determined by fibrosis index, hepatic protein content, microsomal activity, and nature of drug. J Pharmacol Exp Ther (2002) 0.93
Non-invasive assessment of the effect of formulation excipients on stratum corneum barrier function in vivo. Int J Pharm (2004) 0.93
Use of multiphoton tomography and fluorescence lifetime imaging to investigate skin pigmentation in vivo. J Biomed Opt (2013) 0.92
Dermatopharmacokinetic prediction of topical drug bioavailability in vivo. J Invest Dermatol (2006) 0.92
Computational strategies unravel and trace how liver disease changes hepatic drug disposition. J Pharmacol Exp Ther (2008) 0.92
Renal biomarkers predict nephrotoxicity after paraquat. Toxicol Lett (2013) 0.92
Modeling the human skin barrier--towards a better understanding of dermal absorption. Adv Drug Deliv Rev (2012) 0.92
Using laser microporation to improve transdermal delivery of diclofenac: Increasing bioavailability and the range of therapeutic applications. Eur J Pharm Biopharm (2011) 0.91
Inadequate antimicrobial prophylaxis during surgery: a study of beta-lactam levels during burn debridement. J Antimicrob Chemother (2007) 0.91
Plasma acetate, gluconate and interleukin-6 profiles during and after cardiopulmonary bypass: a comparison of Plasma-Lyte 148 with a bicarbonate-balanced solution. Crit Care (2011) 0.91
The effect of formulation on the penetration of coated and uncoated zinc oxide nanoparticles into the viable epidermis of human skin in vivo. Eur J Pharm Biopharm (2013) 0.91
Expression and antioxidant function of liver fatty acid binding protein in normal and bile-duct ligated rats. Eur J Pharmacol (2007) 0.90
Time-correlated single photon counting for simultaneous monitoring of zinc oxide nanoparticles and NAD(P)H in intact and barrier-disrupted volunteer skin. Pharm Res (2011) 0.90
Mathematical models of skin permeability: an overview. Int J Pharm (2011) 0.90
Pharmacokinetics of digoxin cross-reacting substances in patients with acute yellow Oleander (Thevetia peruviana) poisoning, including the effect of activated charcoal. Ther Drug Monit (2006) 0.90
Determination of the effect of lipophilicity on the in vitro permeability and tissue reservoir characteristics of topically applied solutes in human skin layers. J Invest Dermatol (2003) 0.90
Pig ear skin ex vivo as a model for in vivo dermatopharmacokinetic studies in man. Pharm Res (2006) 0.90
Effect of propylene glycol on ibuprofen absorption into human skin in vivo. J Pharm Sci (2008) 0.89
Applications of multiphoton tomographs and femtosecond laser nanoprocessing microscopes in drug delivery research. Adv Drug Deliv Rev (2011) 0.89
Pro re nata medication for psychoses: the knowledge and beliefs of doctors and nurses. Aust N Z J Psychiatry (2002) 0.88
Mathematical and pharmacokinetic modelling of epidermal and dermal transport processes. Adv Drug Deliv Rev (2012) 0.86
Are commercially available nanoparticles safe when applied to the skin? J Biomed Nanotechnol (2010) 0.86
Frequency and thermal effects on the enhancement of transdermal transport by sonophoresis. J Control Release (2003) 0.85
The pharmacokinetics of cefazolin in patients undergoing elective & semi-elective abdominal aortic aneurysm open repair surgery. BMC Anesthesiol (2011) 0.85
β-lactam pharmacokinetics and pharmacodynamics in critically ill patients and strategies for dose optimization: a structured review. Clin Exp Pharmacol Physiol (2012) 0.85
Skin solubility determines maximum transepidermal flux for similar size molecules. Pharm Res (2009) 0.84
Ion-trapping, microsomal binding, and unbound drug distribution in the hepatic retention of basic drugs. J Pharmacol Exp Ther (2003) 0.84
Erbium:YAG fractional laser ablation for the percutaneous delivery of intact functional therapeutic antibodies. J Control Release (2011) 0.84
Pro re nata medication for psychoses: an audit of practice in two metropolitan hospitals. Aust N Z J Psychiatry (2002) 0.84
Quantitative evaluation of altered hepatic spaces and membrane transport in fibrotic rat liver. Hepatology (2002) 0.84
Surfactant protein expression in human skin: evidence and implications. J Invest Dermatol (2006) 0.83
Prediction of paraquat exposure and toxicity in clinically ill poisoned patients: a model based approach. Br J Clin Pharmacol (2014) 0.83
Contributions of electromigration and electroosmosis to peptide iontophoresis across intact and impaired skin. J Control Release (2005) 0.83
Toward a new age of cellular pharmacokinetics in drug discovery. Drug Metab Rev (2011) 0.83
Quantum dot penetration into viable human skin. Nanotoxicology (2011) 0.83
Tissue accumulation of cephalothin in burns: a comparative study by microdialysis of subcutaneous interstitial fluid cephalothin concentrations in burn patients and healthy volunteers. Antimicrob Agents Chemother (2008) 0.83
Transcutaneous vaccination via laser microporation. J Control Release (2012) 0.82
Intravital multiphoton imaging of the selective uptake of water-dispersible quantum dots into sinusoidal liver cells. Small (2014) 0.82
Simple rules defining the potential of compounds for transdermal delivery or toxicity. Pharm Res (2004) 0.82
Measurement of tissue cortisol levels in patients with severe burns: a preliminary investigation. Crit Care (2009) 0.82
Comparative efficacy of oral extended-release hydromorphone and immediate-release hydromorphone in patients with persistent moderate to severe pain: two randomized controlled trials. J Pain Symptom Manage (2005) 0.82
Development of a quality use of medicines coding system to rate clinical pharmacists' medication review recommendations. Pharm World Sci (2003) 0.82
In silico representation of the liver-connecting function to anatomy, physiology and heterogeneous microenvironments. Conf Proc IEEE Eng Med Biol Soc (2004) 0.82
Next generation intra- and transdermal therapeutic systems: using non- and minimally-invasive technologies to increase drug delivery into and across the skin. Eur J Pharm Sci (2013) 0.82
Effect of vehicle pretreatment on the flux, retention, and diffusion of topically applied penetrants in vitro. Pharm Res (2003) 0.81
Compatibility studies of acyclovir and lactose in physical mixtures and commercial tablets. Eur J Pharm Biopharm (2009) 0.81
Controlled non-invasive transdermal iontophoretic delivery of zolmitriptan hydrochloride in vitro and in vivo. Eur J Pharm Biopharm (2008) 0.81
Pharmacokinetic evaluation of fluconazole in critically ill patients. Expert Opin Drug Metab Toxicol (2011) 0.81
Capillary zone electrophoresis for the estimation of transdermal iontophoretic mobility. J Pharm Sci (2005) 0.81
In vitro and in vivo evaluation of the transdermal iontophoretic delivery of sumatriptan succinate. Eur J Pharm Biopharm (2006) 0.81
Non-invasive iontophoretic delivery of peptides and proteins across the skin. Expert Opin Drug Deliv (2011) 0.80